...
首页> 外文期刊>Marine biotechnology >Alginate Microencapsulation for Oral Immunisation of Finfish: Release Characteristics, Ex Vivo Intestinal Uptake and In Vivo Administration in Atlantic Salmon, Salmo salar L.
【24h】

Alginate Microencapsulation for Oral Immunisation of Finfish: Release Characteristics, Ex Vivo Intestinal Uptake and In Vivo Administration in Atlantic Salmon, Salmo salar L.

机译:海藻酸盐微胶囊化对鳍鱼的口服免疫:大西洋鲑,鲑鲑鱼的释放特性,离体肠道吸收和体内给药。

获取原文
获取原文并翻译 | 示例

摘要

This study examined the feasibility of alginate microcapsules manufactured using a low-impact technology and reagents to protect orally delivered immunogens for use as immunoprophylactics for fish. Physical characteristics and protein release kinetics of the microcapsules were examined at different pH and temperature levels using a microencapsulated model protein, bovine serum albumin (BSA). Impact of the microencapsulation process on contents was determined by analysing change in bioactivity of microencapsulated lysozyme. Feasibility of the method for oral immunoprophylaxis of finfish was assessed using FITC-labelled microcapsules. These were applied to distal intestinal explants of Atlantic salmon (Salmo salar) to investigate uptake ex vivo. Systemic distribution of microcapsules was investigated by oral administration of FITC-labelled microcapsules to Atlantic salmon fry by incorporating into feed. The microcapsules produced were structurally robust and retained surface integrity, with a modal size distribution of 250-750 nm and a tendency to aggregate. Entrapment efficiency of microencapsulation was 51.2 % for BSA and 43.2 % in the case of lysozyme. Microcapsules demonstrated controlled release of protein, which increased with increasing pH or temperature, and the process had no significant negative effect on bioactivity of lysozyme. Uptake of fluorescent-labelled microcapsules was clearly demonstrated by intestinal explants over a 24-h period. Evidence of microcapsules was found in the intestine, spleen, kidney and liver of fry following oral administration. Amenability of the microcapsules to intestinal uptake and distribution reinforced the strong potential for use of this microencapsulation method in oral immunoprophylaxis of finfish using sensitive immunogenic substances.
机译:这项研究检验了使用低影响技术制造的藻酸盐微胶囊和保护鱼类口服免疫原作为鱼类免疫预防剂的可行性。使用微囊化的模型蛋白牛血清白蛋白(BSA)在不同的pH和温度水平下检查了微囊的物理特性和蛋白释放动力学。通过分析微囊化溶菌酶的生物活性变化来确定微囊化过程对内容物的影响。使用FITC标记的微胶囊评估了有鳍鱼口服免疫预防方法的可行性。这些被应用于大西洋鲑(Salmo salar)的远端肠外植体以研究离体吸收。通过将FITC标记的微胶囊通过掺入饲料中对大西洋鲑鱼进行口服给药,研究了微胶囊的系统分布。所生产的微胶囊结构坚固且保留了表面完整性,具有250-750 nm的模态尺寸分布并有聚集的趋势。 BSA的微囊包封率为51.2%,溶菌酶为43.2%。微胶囊证明了蛋白质的控制释放,该释放随pH或温度的升高而增加,并且该过程对溶菌酶的生物活性没有明显的负面影响。肠外植体在24小时内清楚地证明了荧光标记的微胶囊的摄取。口服后,在鱼苗的肠,脾,肾和肝中发现了微胶囊。微胶囊对肠道吸收和分布的适应性增强了这种微囊化方法在使用敏感的免疫原性物质进行的有鳍鱼类的口服免疫预防中的强大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号